Searched for
INJECTABLE DIABETES SEGMENT
Mankind Pharma inks in-licensing pact with China's Chongqing Chenan BiopharmaceuticalMankind Pharma has secured an exclusive agreement with Chongqing Chenan Biopharmaceutical. This partnership focuses on commercialising two ...- Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...
- MOFSL stays bullish on Sun Pharma; sees 16% upside on innovation pipelineSun Pharma's June quarter results met analyst expectations, signaling future growth. The company is expanding its specialty and innovative ...
- Tariff on generic drugs: Loud announcement, little consequence? 7 pharma stocks with upside potential of up to 31%The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...
- US market drag keeps Dr Reddy's, Cipla under pressure despite strong product pipelineIndian pharmaceutical firms experienced a challenging June quarter, marked by declining US business profits. Dr Reddy's and Cipla saw signi...
- Domestic formulations, chronic therapies to drive Pharma Q1; US generics remain dragThe healthcare sector anticipates strong growth in domestic formulations and emerging markets. Companies with less US generics dependence w...
- For investors with ability – and patience to wait 3 years, not 3 months: 6 large-cap stocks with upside potential of up to 33%The interesting point about the large-cap space today is not that prices have collapsed. In most cases, they have not. The more important c...
- These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...
- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- Alkem Laboratories launches semaglutide in India at Rs 450 per week, eyes booming weight-loss marketAlkem Laboratories has launched a new semaglutide injection in India. This drug targets the growing diabetes and weight loss market. It is ...
- Zydus Lifesciences in focus after USFDA clears Ahmedabad plant, Aflibercept biosimilar launchZydus Lifesciences is in focus after receiving USFDA clearance with zero observations for its Ahmedabad facility and launching ANYRA, India...
- Weight-loss therapy goes pill-to-shot with higher efficacy, convenienceSales of Novo Nordisk’s oral weight-loss drug Rybelsus have plateaued as Indians increasingly shift to injectable GLP-1 drugs like Eli Lill...
- India's anti-obesity drug market has grown more than fourfold in the last five yearsIndia's anti-obesity drug market has surged, growing over fourfold in five years, reaching ₹576 crore by March 2025, driven by lifestyle di...
- India’s anti-obesity drug market quadruples in five years on lifestyle disease surgeIndia's anti-obesity drug market has surged, growing over fourfold in five years, reaching Rs 576 crore by March 2025. Semaglutide pill Ryb...
- Lupin, Eli Lilly join hands for insulin launchLupin said it will market Eglucent through its own specialty field force while Lilly will be responsible for manufacturing and import.
- Lupin partners Eli Lilly to market diabetes drug 'Eglucent'According to the agreement, Lupin will market and sell Eglucent through its own specialty field force while Lilly will be responsible for m...
- Novo Nordisk to launch insulin injection Tresiba in IndiaInsulin player Novo Nordisk said it is launching long-lasting insulin injection Tresiba in the country soon.
- Zydus to invest Rs 100 crore in Vadodara unit, expand hospital businessZydus Hospitals & Healthcare Research recently started its first hospital operations at Anand, better known as Amul's hometown.
- Eli Lilly aims to be among top 20 pharma companies in India by 2020US-based pharmaceutical major Eli Lilly and Company expects to be among the top 20 drug makers in India by 2020
- Diabetic drug co USV takes a shot at injectiblesUSV, the largest anti-diabetic drug maker in India, is planning to enter the injectibles segment. The company will inaugurate its first inj...
Load More
